The deadline for implementation of the new elemental impurities guidelines for drug products and ingredients is fast approaching. Implementation is scheduled for January 2018, by which time manufacturers of pharmaceutical drug products must comply with USP <232>/<233> and ICH Q3D.
Recent harmonization between USP <232> and ICH Q3D, has resulted in complete alignment of the number of analytes and PDEs. In this webinar we will summarize the most recent updates.
Brought to you by: